A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab

* Diagnosis of histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum. * Primary tumor has been resected \> 3 months prior to randomization. * At least 1 lesion on a computed tomography (CT) scan (preferred) or magnetic resonance imaging (MRI) that is measurable as defined by Response Evaluation Criteria In Solid Tumors (RECIST), Version 1.1. * Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1. * Progression following treatment with fluoropyrimidine/oxaliplatin/bevacizumab-regimen in the metastatic setting. * Adequate hematologic, renal and hepatic function.

* Any prior therapy with irinotecan * Unresolved clinically significant toxicities from prior anticancer therapy, defined as any Common Terminology Criteria for Adverse Events (CTCAE) =\> Grade 2 * Clinically significant conditions that increase the risk for antiangiogenic therapy. * History of any of the following during first-line therapy with a bevacizumab-containing regimen: arterial thrombotic/thromboembolic event, bowel perforation, Grade 4 hypertension, Grade 3 proteinuria or Grade 3 - 4 bleeding event.